ArticleJournal of biological engineering2026
Curcumin-loaded silk fibroin scaffold promotes cartilage regeneration by inhibiting angiogenesis via Drp1/ROS-mediated mitochondrial regulation.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Articular cartilage injury often leads to vascular endothelial cell (VEC) infiltration, disrupting the microenvironment between cartilage and subchondral bone, thereby compromising cartilage repair quality. Curcumin (Cur) is a natural polyphenol with anti-inflammatory and anti-angiogenic properties that holds promise for therapeutic applications. However, its clinical utility is limited due to poor solubility and instability. To address these challenges, we developed a curcumin-loaded silk fibroin nanoparticle (Cur-SN) delivery system to inhibit VEC infiltration and promote cartilage regeneration. Cur-SNs were prepared and characterised to evaluate their physicochemical properties. The effects of Cur-SN on VEC apoptosis and senescence were assessed, and the underlying mechanism by which Cur-SN regulates mitochondrial homeostasis via the Drp1/ROS pathway was investigated. Additionally, a rat knee cartilage defect model was established, in which Cur-SN combined with a BMSC-loaded hydrogel was implanted. Cartilage differentiation and VEC infiltration levels in newly formed tissues were subsequently analysed. In vitro experiments demonstrated that Cur-SN upregulated Drp1 and ROS levels, leading to mitochondrial homeostasis disruption. This, in turn, induced VEC apoptosis and senescence while significantly inhibited VEC infiltration. Furthermore, Cur-SN effectively counteracted the inhibitory effects of VEC activation on BMSC chondrogenic differentiation. In vivo experiments revealed that Cur-SN reduced VEC infiltration and angiogenesis in newly formed tissues, thereby promoting hyaline cartilage regeneration at the defect site. Cur-SN enhances cartilage repair by upregulating Drp1 expression and ROS levels, thereby disrupting mitochondrial homeostasis, inducing VEC apoptosis and senescence, and inhibiting VEC infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.